Alessandro Giani

Dr. Alessandro Giani

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
RBRaoul J. P. Bonnal
Raoul J. P. Bonnal
GRGrazisa Rossetti
Grazisa Rossetti
ELEnrico Lugli
Enrico Lugli
MSMarco De Simone
Marco De Simone
PGPaola Gruarin
Paola Gruarin
MPMassimiliano Pagani
Massimiliano Pagani

1 October 2018 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SFSimone Famularo
Simone Famularo
SSStefano Di Sandro
Stefano Di Sandro
AGAlessandro Giani
Alessandro Giani
Andrea LauterioAndrea Lauterio
Andrea Lauterio
MSMarta Sandini
Marta Sandini
LCLuciano De Carlis
Luciano De Carlis

21 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AGAlessandro Giani
Alessandro Giani
FCFederica Cipriani
Federica Cipriani
SFSimone Famularo
Simone Famularo
Matteo DonadonMatteo Donadon
Matteo Donadon
DBDavide P. Bernasconi
Davide P. Bernasconi
LGLuca Gianotti
Luca Gianotti
Background: We aimed to assess the ability of comprehensive complication index (CCI) and Clavien-Dindo complication (CDC) scale to predict excessive length of hospital stay (e-LOS) in patients undergoing liver resection for hepatocellular carcinoma. Methods: Patients were identified from an Italian multi-institutional database and randomly selected to be included in either a derivation or validation set. Multivariate logistic regression models and ROC curve analysis including either CCI or CDC as predictors of e-LOS were fitted to compare predictive performance. E-LOS was defined as a LOS longer than the 75th percentile among patients with at least one complication. Results: A total of 2669 patients were analyzed (1345 for derivation and 1324 for validation). The odds ratio (OR) was 5.590 (95%CI 4.201; 7.438) for CCI and 5.507 (4.152; 7.304) for CDC. The AUC was 0.964 for CCI and 0.893 for CDC in the derivation set and 0.962 vs. 0.890 in the validation set, respectively. In patients with at least two complications, the OR was 2.793 (1.896; 4.115) for CCI and 2.439 (1.666; 3.570) for CDC with an AUC of 0.850 and 0.673, respectively in the derivation cohort. The AUC was 0.806 for CCI and 0.658 for CDC in the validation set. Conclusions: When reporting postoperative morbidity in liver surgery, CCI is a preferable scale.

22 September 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SFSimone Famularo
Simone Famularo
SSStefano Di Sandro
Stefano Di Sandro
AGAlessandro Giani
Alessandro Giani
Andrea LauterioAndrea Lauterio
Andrea Lauterio
MSMarta Sandini
Marta Sandini
LCLuciano De Carlis
Luciano De Carlis

2 November 2022 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
TRTess M E van Ramshorst
Tess M E van Ramshorst
AGAlessandro Giani
Alessandro Giani
MMMichele Mazzola
Michele Mazzola
SDSafi Dokmak
Safi Dokmak
FFFadhel Samir Ftériche
Fadhel Samir Ftériche
FSfor the European Consortium on Minimally Invasive Pancreatic Surgery
for the European Consortium on Minimally Invasive Pancreatic Surgery
Background: Benchmarking is an important tool for quality comparison and improvement. However, no benchmark values are available for minimally invasive spleen-preserving distal pancreatectomy, either laparoscopically or robotically assisted. The aim of this study was to establish benchmarks for these techniques using two different methods. Methods: Data from patients undergoing laparoscopically or robotically assisted spleen-preserving distal pancreatectomy were extracted from a multicentre database (2006–2019). Benchmarks for 10 outcomes were calculated using the Achievable Benchmark of Care (ABC) and best-patient-in-best-centre methods. Results: Overall, 951 laparoscopically assisted (77.3 per cent) and 279 robotically assisted (22.7 per cent) procedures were included. Using the ABC method, the benchmarks for laparoscopically assisted and robotically assisted spleen-preserving distal pancreatectomy respectively were: 150 and 207 min for duration of operation, 55 and 100 ml for blood loss, 3.5 and 1.7 per cent for conversion, 0 and 1.7 per cent for failure to preserve the spleen, 27.3 and 34.0 per cent for overall morbidity, 5.1 and 3.3 per cent for major morbidity, 3.6 and 7.1 per cent for pancreatic fistula grade B/C, 5 and 6 days for duration of hospital stay, 2.9 and 5.4 per cent for readmissions, and 0 and 0 per cent for 90-day mortality. Best-patient-in-best-centre methodology revealed milder benchmark cut-offs for laparoscopically and robotically assisted procedures, with operating times of 254 and 262.5 min, blood loss of 150 and 195 ml, conversion rates of 5.8 and 8.2 per cent, rates of failure to salvage spleen of 29.9 and 27.3 per cent, overall morbidity rates of 62.7 and 55.7 per cent, major morbidity rates of 20.4 and 14 per cent, POPF B/C rates of 23.8 and 24.2 per cent, duration of hospital stay of 8 and 8 days, readmission rates of 20 and 15.1 per cent, and 90-day mortality rates of 0 and 0 per cent respectively. Conclusion: Two benchmark methods for minimally invasive distal pancreatectomy produced different values, and should be interpreted and applied differently.

20 April 2022 in Nutrition
Verified
Journal Article
Closed access
MGMarco Giani
Marco Giani
EREmanuele Rezoagli
Emanuele Rezoagli
AGAlice Grassi
Alice Grassi
MPMarco Porta
Marco Porta
LRLuca Riva
Luca Riva
AGAlessandro Giani
Alessandro Giani